---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010763"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:12:07.475170+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aclaris stockholders approve doubling of authorized shares to 200M at annual meeting

## Summary
- Amendment to authorized common stock from 100M to 200M shares approved: 60.7M for, 547K against, 3.4M abstain.
- All three director nominees elected: Mehra 58.4M for, Powell 39.3M for, Gowen 57.3M for (Powell had 20.6M withheld).
- Advisory say-on-pay approved: 58.6M for, 1.2M against, 28K abstain.
- Ratification of PwC as auditor approved: 64.7M for, 16K against, 13K abstain.
- Meeting turnout: 91.56% of 70.7M outstanding shares represented.

## SEC filing metadata
- accession: 0001558370-23-010763
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/acrs-20230601x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010763
- JSON: https://secwatch.observer/filing/0001558370-23-010763.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010763.txt

## Key facts
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares at the 2023-06-01 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal No. 3 : Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 shares to 200,000,000 shares .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal No. 2 : Advisory approval of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Election of three nominees to serve as directors at the 2023-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal No. 1 : Election of three nominees to serve as directors on the Board of Directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm
- Shareholder Votes
  Aclaris Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: Proposal No. 4 : Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023010763/0001558370-23-010763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.